This page shows the latest Pifzer news and features for those working in and with pharma, biotech and healthcare.
Researchers noted it is 'unclear' what effect this reduction has on the vaccine's protection against the variant
BioNTech is also planning to publish an additional analysis of its Pifzer-partnered vaccine's efficacy against the coronavirus strain identified in South Africa.
BioNTech is planning to publish analysis on vaccine's efficacy against South African variant
Companies share additional phase 1 safety and tolerability data
Other PD-1/PD-L1 inhibitors approved for use are AstraZeneca’s Imfinzi, Pifzer and Merck’s Bavencio and Roche’s Tecentriq, and the latter is currently being explored in a
Also waiting in the wings could be volasertib from Boehringer Ingelheim, which is currently in phase III clinical trials, and Pifzer's Mylotarg, which would be reintroduced to the market after
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...